Correction to: A Phase II Study Evaluating Combined Neoadjuvant Cetuximab and Chemotherapy Followed by Chemoradiotherapy and Concomitant Cetuximab in Locoregional Oesophageal Cancer Patients by Alsina, M. et al.
CORRECTION
Correction to: A Phase II Study Evaluating Combined Neoadjuvant
Cetuximab and Chemotherapy Followed by Chemoradiotherapy
and Concomitant Cetuximab in Locoregional Oesophageal
Cancer Patients
Maria Alsina1 & Fernando Rivera2 & Francisco Javier Ramos1 & Maica Galán3 & Rafael López4 & Pilar García-Alfonso5 &
José Enrique Alés-Martinez6,7 & Bernardo Queralt8 & Antonio Antón9 & Alfredo Carrato10 & Cristina Grávalos11 &
Maria José Méndez-Vidal12 & Carlos López2 & Inmaculada Ruiz de Mena13 & Josep Tabernero1 & Jordi Giralt14 &
Enrique Aranda12 & on behalf of the Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD) and
Grupo de Investigación Clínica en Oncología Radioterápica (GICOR)
Published online: 14 December 2017
# Springer International Publishing AG, part of Springer Nature 2017
Correction to: Targ Oncol
https://doi.org/10.1007/s11523-017-0536-z
Errors were subsequently identified in the article and the fol-
lowing corrections should be noted:
The title of the article, which previously read BCetuximab/
TPF/radiotherapy in oesophageal cancer^
should read: A Phase II Study Evaluating Combined
Neoadjuvant Cetuximab and Chemotherapy Followed by
Chemoradiotherapy and Concomitant Cetuximab in
Locoregional Oesophageal Cancer Patients.
The original article was corrected.
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